Ultima Genomics, Inc.

Ultima Genomics is an American biotechnology company that develops and manufactures systems for high-throughput DNA sequencing. Its mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company is headquartered in Fremont, California.

Ultima Genomics' core offering centers on its revolutionary sequencing architecture, designed to significantly reduce the cost of sequencing and overcome traditional limitations in the breadth, depth, and frequency of genomic data. Key products include the UG 100™ and UG200™ Series sequencing platforms, which utilize a unique open silicon wafer technology instead of conventional flow cells for ultra-high-throughput and cost-effective DNA sequencing. These platforms support a diverse range of applications, including germline whole genome sequencing, oncology applications like liquid biopsy and minimal residual disease detection using ppmSeq™, single-cell sequencing, proteomics, epigenomics, and transcriptomics.

Founded in 2016 by Gilad Almogy and Mark Pratt, Ultima Genomics has secured over $600 million in venture capital funding. Recent advancements include the February 2026 launch of the UG200™ Series and Solaris 2.0 workflows, which offer increased output and enhanced performance. The company is expanding its global presence through partnerships with genomic service providers and is actively engaged in collaborations, such as the Trillion Gene Atlas project with Basecamp Research, leveraging its technology for large-scale biological data generation crucial for AI applications. Ultima Genomics positions itself as a market disruptor, aiming to democratize access to genomic data by substantially lowering sequencing costs.